Historically, cancer patients with autoimmune disease likes lupus, Type 1 diabetes and rheumatoid arthritis have been excluded from clinical trials studying immune checkpoint inhibitors. As a result, they haven’t been able to receive these immunotherapy drugs, which turn off the brakes of T cells to allow them to more effectively attack cancer cells.

“There are more than 80 different types of autoimmune diseases that affect 24...